跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 77 条关于
“DLL4”
全部
77
临床试验
30
药物
16
机构
0
资讯
31
去年
Compass Therapeutics Receives FDA Fast Track Designation for CTX-009 Bispecific Antibody
去年
Compass Therapeutics Advances Pipeline with New Bispecific Antibody Candidate
去年
Compass Therapeutics Reports Promising Clinical Data Across Bispecific Antibody Pipeline
8个月前
Compass Therapeutics Advances Multiple Bispecific Antibody Programs with Key Biliary Tract Cancer Data Expected Q1 2026
去年
Organoid Technology Advances Diabetes Research with Sophisticated 3D Models and Therapeutic Applications
去年
FDA Grants Accelerated Approval to Tarlatamab for Previously Treated Extensive-Stage Small Cell Lung Cancer
去年
DLL3-Targeted Therapies Show Promise in Neuroendocrine Prostate Cancer
2年前
DLL3-Targeted Therapies Show Promise in Neuroendocrine Prostate Cancer
8个月前
AbbVie Secures $1.1B Deal for Zelgen's DLL3-Targeting Cancer Therapy
去年
DLL3-Targeted ADC ZL-1310 Shows Promise in Extensive-Stage Small Cell Lung Cancer
第 1 页,共 4 页
上一页
下一页